Literature DB >> 7308242

Pharmacokinetics and metabolism of 14C-labelled alinidine in man and dogs.

D Arndts, G Leb, H J Förster.   

Abstract

Radioactively labelled alinidine was administered intravenously (10 mg) and orally (40 mg) to 5 healthy volunteers and beagle dogs (3 animals for each administration route: 0.1 mg/kg body weight i.v. and 1 mg/kg body weight p.o.). Alinidine was totally absorbed in both species. Regardless of the route of administration man excreted the drug via the kidneys within 12 hours, almost entirely in the unchanged form. The blood plasma curves in man followed a multiexponential decline (t 1/2 alpha : 35 sec, t 1/2 beta : 44 min, t 1/2 gamma : 210 min). The maximum plasma levels of the drug were recorded in man, 45 min after oral administration. However, the rather slow decline of plasma radioactivity observed in dogs, corresponded well with the delayed urinary excretion of alinidine (50% of the administered dose) in this species. Dogs metabolized the drug extensively; seven different metabolites including the parent compound were isolated from canine urine. considerable interindividual differneces were found concerning the quantitive but not the qualitative metabolic pattern of alinidine in dogs. Structural analysis by mass spectrometry revealed oxidation, hydroxylation, and cleavage products of alinidine, altered in its imidazolin and/or allylic moiety. In both species no traces of clonidine were found, which was a predicted metabolite formed by the removal of the allylic sidechain of alinidine.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7308242     DOI: 10.1007/BF03189492

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  12 in total

1.  Identification of 2, 6-dichlorophenylguanidine as a metabolite of clonidine.

Authors:  P Hodges
Journal:  J Pharm Pharmacol       Date:  1976-01       Impact factor: 3.765

2.  Clinical pharmacology and pharmacokinetics of clonidine.

Authors:  C T Dollery; D S Davies; G H Draffan; H J Dargie; C R Dean; J L Reid; R A Clare; S Murray
Journal:  Clin Pharmacol Ther       Date:  1976-01       Impact factor: 6.875

3.  [Metabolite isolation for mass spectrometrical determination of new drugs (author's transl)].

Authors:  D Arndts; K L Rominger
Journal:  Arzneimittelforschung       Date:  1978

4.  [Studies on the pharmacokinetics and on the metabolism of 2(2,6-dichlorphenylamino)-2-imidazoline-hydrochloride (St 155)].

Authors:  D Rehbinder; W Deckers
Journal:  Arzneimittelforschung       Date:  1969-02

5.  The pharmacokinetics and metabolism of Kö592 in man, dog and rat.

Authors:  D Arndts; W Pollmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1973       Impact factor: 3.000

6.  Cardiovascular actions of N-allyl-clonidine (ST 567), a substance with specific bradycardic action.

Authors:  W Kobinger; C Lillie; L Pichler
Journal:  Eur J Pharmacol       Date:  1979-09-15       Impact factor: 4.432

7.  [Metabolic degradation of clonidine (author's transl)].

Authors:  S Darda; H J Förster; H Sthle
Journal:  Arzneimittelforschung       Date:  1978

8.  A newly developed precise and sensitive radioimmunoassay for clonidine.

Authors:  D Arndts; H Stähle; C J Struck
Journal:  Arzneimittelforschung       Date:  1979

9.  Haemodynamic and electrophysiologic actions of alinidine in the dog.

Authors:  W Traunecker; A Walland
Journal:  Arch Int Pharmacodyn Ther       Date:  1980-03

10.  Alinidine reduces heart-rate without blockade of beta-adrenoceptors.

Authors:  D W Harron; J G Riddell; R G Shanks
Journal:  Lancet       Date:  1981-02-14       Impact factor: 79.321

View more
  3 in total

1.  Proof of the linearity of the pharmacokinetics of alinidine in man.

Authors:  D Arndts; H Warnkross; K L Rominger; H Justus
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

2.  New aspects in the metabolism of alinidine in man.

Authors:  D Arndts; H J Forster
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1981       Impact factor: 2.441

3.  Blood level, distribution, metabolite pattern and excretion of [14C]alinidine in mice and rats.

Authors:  W D Bechtel; I Richter
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Jul-Sep       Impact factor: 2.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.